Verastem Oncology (Nasdaq: VSTM) released preliminary data from its ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE